Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 Vaccine for Children 5-11 Years						Print
																Related Pages
										On This Page
			OverviewIntroductionMethodsResultsGRADE Summary
Overview
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for children aged 5─11 years was presented to the Advisory Committee for Immunization Practices (ACIP) on November 2, 2021. GRADE evidence type indicates the certainty in estimates from the available body of evidence. Evidence certainty ranges from type 1 (high certainty) to type 4 (very low certainty) [*1*].
The policy question was, “Should vaccination with Pfizer-BioNTech COVID-19 vaccine (2 doses, 10 μg) be recommended for children aged 5─11 years under an Emergency Use Authorization?” The potential benefits pre-specified by the ACIP COVID-19 Vaccines Work Group included prevention of the following outcomes: symptomatic laboratory-confirmed COVID-19 (critical), hospitalization due to COVID-19 (important), multisystem inflammatory syndrome in children (MIS-C) (important), and asymptomatic SARS-CoV-2 infection (important). The two pre-specified harms were serious adverse events (SAEs) (critical) and reactogenicity grade ≥3 (important).
A systematic review of evidence on the efficacy and safety of a two-dose regimen of Pfizer-BioNTech COVID-19 vaccine among children 5─11 years was conducted. The quality of evidence from one Phase II/III randomized controlled trial (RCT) was assessed using a modified GRADE approach.
A lower risk of symptomatic COVID-19 was observed with vaccination compared with placebo (relative risk [RR] 0.10; 95% confidence interval [CI]: 0.03─0.31; evidence type 1). The available data indicated that SAEs were more common in vaccine recipients, but certainty in the estimate was very low (RR 0.49; 95% CI 0.03─7.89; evidence type 4), and none of these SAEs were assessed by the Food and Drug Administration (FDA) as related to study intervention. Reactogenicity grade ≥3 was associated with vaccination (RR 2.53; 95% CI 1.19─5.38; evidence type 2). About 2.7% of vaccine recipients and 1.1% of placebo recipients reported any grade ≥3 local or systemic reactions following either dose 1 or dose 2.Introduction
On October 29, 2021, the FDA updated the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 (BNT162b2) vaccine for prevention of symptomatic COVID-19 to include children aged 5─11 years [*2*]. As part of the process employed by the ACIP, a systematic review and GRADE evaluation of the evidence for Pfizer-BioNTech COVID-19 vaccine was conducted and presented to ACIP. The ACIP adopted a modified GRADE approach in 2010 as the framework for evaluating the scientific evidence that informs recommendations for vaccine use. Evidence of benefits and harms were reviewed based on the GRADE approach [*1*].
The policy question was, “Should vaccination with Pfizer-BioNTech COVID-19 vaccine (2 doses, 10 μg) be recommended for children aged 5─11 years under an Emergency Use Authorization?” (Table 1).Methods
We conducted a systematic review of evidence on the efficacy and safety of a two-dose regimen (10 μg per dose) of Pfizer-BioNTech COVID-19 vaccine in children aged 5─11 years. We assessed outcomes and evaluated the quality of evidence using a modified GRADE approach.
During Work Group calls, members were asked to pre-specify and rate the importance of relevant patient-important outcomes (including benefits and harms) before the GRADE assessment. No conflicts of interest were reported by CDC and ACIP COVID-19 Vaccines Work Group members involved in the GRADE analysis. Outcomes of interest included individual benefits and harms (Table 2). The critical benefit of interest was prevention of symptomatic laboratory-confirmed COVID-19. Other important outcomes included prevention of hospitalization due to COVID-19, prevention of MIS-C, and prevention of asymptomatic SARS-CoV-2 infection. The critical harm of interest was serious adverse events, including death; reactogenicity grade ≥3 was deemed an important harm. Hospitalization, MIS-C, and asymptomatic SARS-CoV2 infection were not included in the evidence profile because no data were available.
We identified clinical trials through clinicaltrials.gov. Records of relevant Phase I, II, or III RCTs of COVID-19 vaccine were included if they 1) provided data on children aged 5─11 years vaccinated with BNT162b2; 2) involved human subjects; 3) reported primary data; and 4) included data relevant to the efficacy and safety outcomes being measured. We identified relevant observational studies through an ongoing systematic review conducted by the International Vaccine Access Center (IVAC) and the World Health Organization (WHO), as previously described [*3*]. Relevant observational studies were restricted to the defined population, intervention, comparison, and outcome outlined in the policy question, or related outcomes if direct data were not available. In addition, unpublished and other relevant data were obtained by hand-searching reference lists, and consulting with vaccine manufacturers and subject matter experts. Characteristics of all included studies are shown in Appendix 1 [4], and evidence retrieval methods are shown in Appendix 2.
Relative risks (RR) were calculated from numerators and denominators available in the body of evidence. Vaccine efficacy estimates were defined as 100% x (1-RR). Immunobridging data comparing geometric mean neutralizing antibody titers (GMTs) in 5─11-year-olds to those in 16─25-year-olds in whom clinical efficacy was previously established was used in support of efficacy; geometric mean ratios and 95 study records.
The evidence certainty assessment addressed risk of bias, inconsistency, indirectness, imprecision, and other characteristics. The GRADE assessment across the body of evidence for each outcome was presented in an evidence profile; the evidence certainty of Type 1, 2, 3, or 4 corresponds to high, moderate, low, or very low certainty, respectively.Results
The results of the GRADE assessment were presented to ACIP on November 2, 2021. One study was reviewed that met the criteria for evidence synthesis and provided data on outcomes specified for GRADE (Appendix 1). Data were reviewed from one Phase II/III randomized controlled trial using data provided by the sponsor. The final GRADE assessment was limited to the Phase II/III RCT data. Among children with and without prior evidence of SARS-CoV-2 infection in the all-available efficacy population (all randomized participants who received two doses), the Pfizer-BioNTech COVID-19 vaccine reduced risk of symptomatic laboratory-confirmed COVID-19 when compared with placebo (crude VE: 90.9%;  95% CI: 68.3%─98.3%; based on RR: 0.03; 95% CI: 0.10, 0.31) over a median follow-up of three months (Table 3a, Table 4). Concern for indirectness was noted because of the short duration of follow-up (i.e., observed vaccine efficacy at three months may differ from vaccine efficacy over a longer duration). Among participants without prior evidence of SARS-CoV-2 infection up to 1 month after dose 2, the geometric mean ratio (GMR) of SARS-CoV-2 50% neutralizing antibodies in children 5─11 years compared with persons aged 16─25 years was 1.04 (95% CI: 0.93─1.18), and met the prespecified noninferiority criteria (i.e., lower bound of the 2-sided 95% confidence interval for GMR >0.67 and GMR point estimate was ≥0.8) (Table 3b).  For evaluation of potential harms, data were reviewed from the Phase II/III RCT. Serious adverse events were more common in vaccine recipients, but certainty in the estimate was very low (RR: 0.49; 95% CI: 0.03─7.89). Serious concern of indirectness was noted because the body of evidence does not provide certainty that rare serious adverse events were captured due to the short follow-up and small sample size. There was also very serious concern for imprecision, due to the width of the confidence interval. No SAEs were judged by the investigator to be related to vaccination (Table 3c). No vaccine-associated enhanced disease or deaths occurred in the Phase II/III RCT. Grade ≥3, or severe, local or systemic reactions within 7 days following either dose occurred more frequently in the vaccine group (2.7%) than in the placebo group (1.1%) (Table 3d). No serious concerns impacted the certainty of the estimate of reactogenicity.GRADE Summary
The initial GRADE evidence level was type 1 (high) for each outcome because the body of evidence was from an RCT (Table 4). In terms of benefits, the available data indicated that the vaccine was efficacious for preventing symptomatic, laboratory-confirmed COVID-19, and no serious concerns impacting certainty in the estimate were identified for this outcome (type 1, high). The certainty in the estimate of the effect for serious adverse events was downgraded because of serious concern of indirectness related to the short follow-up (median three months) and very serious concern for imprecision because of the width of the 95% confidence interval (type 4, very low certainty). The certainty in the estimate of effect for reactogenicity was downgraded due to serious concern for imprecision (type 2, moderate) (Table 4).
References
Ahmed F. U.S. Advisory Committee on Immunization Practices (ACIP) Handbook for Developing Evidence-based Recommendations.
Woodworth K, Moulia D, Collins J. et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021. *MMWR Morb Mortal Wkly Rep*. ePub: 5 Nov 2021.
International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub. view-hub.org. Accessed: 11/1/2021.
Pfizer. BNT162b2. Pfizers’s briefing materials. Vaccines and Related Biological Products Advisory Committee. Meeting date: October 26, 2021.Table 1: Policy Question and PICO
Table 1: Policy Question and PICO
Policy question:
Should vaccination with Pfizer-BioNTech COVID-19 vaccine (2-doses, 10 μg) be recommended for children aged 5─11 years under an Emergency Use Authorization?Population
Children aged 5─11 yearsIntervention
Pfizer-BioNTech COVID-19 vaccine BNT162b2 (10 μg, 2 doses IM, 21 days apart)Comparison
No Pfizer-BioNTech COVID-19 vaccineOutcomes
Symptomatic laboratory-confirmed COVID-19
Hospitalization due to COVID-19
Multisystem inflammatory syndrome in children (MIS-C)
Asymptomatic SARS-CoV-2 infection
Serious adverse events
Reactogenicity grade ≥3**Abbreviations**: IM = intramuscular.Table 2: Outcomes and Rankings
Table 2: Outcomes and Rankings
Outcome
Importancea
Included in evidence profileSymptomatic laboratory-confirmed COVID-19
Critical
YesHospitalization due to COVID-19
Important
NoaMultisystem inflammatory syndrome in children (MIS-C)
Important
NoaAsymptomatic SARS-CoV-2 infection
Important
NobSerious adverse events
Critical
YesReactogenicity grade ≥3
Important
Yes
aNo events were observed in study identified in the review of evidence.
bData on outcome not available in studies identified in the review of evidence.Table 3a: Summary of Studies Reporting Symptomatic Laboratory-confirmed COVID-19
Table 3a: Summary of Studies Reporting Symptomatic Laboratory-confirmed COVID-19
Authors last name, pub year
**Age or other characteristic of importance**
n/N intervention
n/N comparison
Comparator
Vaccine Efficacy (95% CI) [100 x (1-IRR)]
Study limitations (Risk of Bias)Pfizer, 2021 [*2*]a,b
Primary outcomec: SARS-CoV-2 RT-PCR-positive symptomatic illnessd, ≥7 days post second dose
3/1,461
16/714
Placebo
90.9% (68.3─98.3%)e
Not serious**Abbreviations:** RT-PCR = real-time polymerase chain reaction; CI = confidence interval; RR = relative risk.
a1,528 and 757 children aged 5–11 years were randomized to vaccine and placebo, respectively.
bBased on data cutoff October 8, 2021; participants had a median follow-up of three months.
cPrimary outcome, defined as SARS-CoV-2 RT-PCR-positive symptomatic illness ≥7 days post second dose.
d Symptomatic illness defined as least one respiratory or other COVID-19-related symptom (fever, cough, shortness of breath, chills, muscle pain, loss of taste/smell, sore throat, diarrhea, vomiting), confirmed with PCR during or ±4 days of symptom onset.
e Vaccine efficacy estimate includes children with and without prior evidence of SARS-CoV-2 infection in the all-available efficacy population (all randomized participants who received two doses).Table 3b: Summary of Studies Reporting Symptomatic Laboratory-confirmed COVID-19 (indirect evidence assessed using immunobridging)
Table 3b: Summary of Studies Reporting Symptomatic Laboratory-confirmed COVID-19 (indirect evidence assessed using immunobridging)
Authors last name, pub year
**Age or other characteristic of importance**
**nc
5-11 Years**
**nc
16-25 Years**
**GMRd
(95%CI)**
**Met Noninferiority Objectivee**
Study limitations (Risk of Bias)Pfizer, 2021 [*2*]
SARS-CoV-2 neutralization assay – NT50a,b
264
253
1.04 (0.93─1.18)
Yes
Not serious**Abbreviations:** NT50 = 50% neutralizing titer; GMR= geometric mean ratio; CI = confidence interval; LLOQ = lower limit of quantitation
aAmong participants who had no serological or virological evidence (up to 1 month after receipt of the last dose) of past SARS-CoV-2 infection, had negative nucleic acid amplification test (NAAT) at any unscheduled visit up to one month after dose two, and had no medical history of COVID-19.
bSampling time point was one month after dose two.
cNumber of subjects with valid and determinate assay results for the specified assay at the given dose and sampling time point.
dGMRs and 2-sided 95% CIs were calculated by exponentiating the mean difference of the logarithms of the titers (Group 1 [5–11 years] – Group 2 [16─25 years]) and the corresponding CI (based on the Student t distribution).
eNoninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67 and the point estimate of the GMR is ≥0.8.Table 3c: Summary of Studies Reporting Serious Adverse Eventsa
Table 3c: Summary of Studies Reporting Serious Adverse Events
Authors last name, pub year
**Age or other characteristic of importance**
**n**b**/N**c**(%) intervention**
**n**b**/N**c**(%) comparison**
Comparator
**RR (95% CI)**
Study limitations (Risk of Bias)Pfizer, 2021 [*2*]
Phase II/III RCT, children aged 5─11 years
1d /1,518 (0.07)
1e /750 (0.2)
Placebo
2.50 (0.49─12.84)
Not seriousaDeath, life-threatening event, hospitalization, incapacity to perform normal life functions, medically important event, or congenital anomaly/birth defect.
bNumber of participants experiencing SAEs (participants may experience more than one SAE), data cutoff October 8, 2021.
cIncluded all randomized participants who received at least 1 dose of vaccine.
dSAE (limb fracture) was reported in a participant in the BNT162b2 group. 3 SAEs (arthritis infective, foreign body ingestion of a penny, epiphyseal fracture) were reported in 3 children (1 each) in the pediatric safety expansion group through the data cut off 8 October 2021. All SAEs were assessed by the investigatory as not related to the study intervention.
e2 SAEs (pancreatitis and abdominal pain) occurred in 1 placebo recipient.Table 3d: Summary of Studies Reporting Reactogenicitya
Table 3d: Summary of Studies Reporting Reactogenicity
Authors last name, pub year
**Age or other characteristic of importance**
**n/N (%) intervention**
**n/N (%) comparison**
Comparator
**RR (95% CI)**
Study limitations (Risk of Bias)Pfizer, 2021 [*2*]b
Phase II/III RCT, children 5─11 years
41c/1,517 (2.7)
8/750 (1.1)
Placebo
2.53 (1.19─5.38)
Not serious
**Abbreviations:**RR = relative risk; CI = confidence interval; RCT = randomized controlled trial.
aReactogenicity outcome includes local and systemic events, grade ≥3. Grade 3: prevents daily routine activity or requires use of a pain reliever. Grade 4: requires emergency room visit or hospitalization. One participant in the vaccine group reported grade 4 pyrexia (40.4 °C).
bBased on interim analysis, data cutoff September 6, 2021.
cNo participants reported a local grade 4 reaction. One participant in the vaccine group reported grade 4 pyrexia (>40.0 °C).Table 4: Grade Summary of Findings Table
Table 4: Grade Summary of Findings Table
Certainty assessment
No of patients Pfizer-BioNTech COVID-19 vaccine
No of patients no vaccine
Effect Relative
(95% CI)
Effect Absolute
(95% CI)
Certainty
ImportanceNo of studies
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerationsSymptomatic laboratory-confirmed COVID-19 (assessed with vaccine efficacy ≥7 days after second dose)1
RCT
not serious
not serious
not seriousa,b,c
not serious
none
3/1,461d (0.2%)
16/714e(2.2%)
**RR 0.10**
(0.03 to 0.31)
**2,017 fewer per 100,000**
(from 2,174 fewer to 1,546)
Type 1
CRITICAL**Serious adverse events**2
RCT
not serious
not serious
seriousf,g
very serioush
none
1/1,518i (0.07%)
1/750j (0.10%)
**RR 0.49**
(0.03 to 7.89)
**68 fewer per 100,000**
(from 129 fewer to 919 more)
Type 4
CRITICAL**Reactogenicity, grade >=3**1
RCT
not serious
not serious
not serious
seriousk
none
41/1,517 (2.7%)
8/750 (1.1%)
**RR 2.53**
(1.19 to 5.38)
**1,632 more per 100,000**
(from 203 fewer to 4,672 more)
Type 2
IMPORTANT
**Abbreviations:**CI = confidence interval; RR = relative risk; COVID-19 = coronavirus disease 2019; RCT = randomized controlled trial.
The RCT excluded children who were immunocompromised or had a prior history of MIS-C. The population included in the RCT may not represent all children aged 5─11 years. However, this was deemed not serious.
Indirectness was considered because the vaccine efficacy observed at a median 3-month follow-up may differ from that observed over a longer period. However, this was deemed not serious.
The effects noted are from an analysis of the observed VE at least 7 days after Dose 2, among children with or without prior evidence of SARS-CoV-2 infection in the all-available efficacy population (all randomized children who received 2 doses). The VE observed at least 7 days after Dose 2 among participant with or without prior evidence of SARS-CoV-2 infection in the evaluable efficacy population (excluded children who received Dose 2 outside the predefined window [19─41 days post Dose 1] or had other protocol deviations [mainly related to vaccine thawing, dilution and/or administration issues]) was 90.7% (95% CI: 67.7─98.3%) with 3 cases in vaccine arm and 16 cases in the placebo arm. The observed VE from the all-available efficacy population with or without prior evidence of SARS-CoV-2 infection was deemed the most directly applicable to the policy question.
Total surveillance time was 369 person-years.
Total surveillance time was 179 person-years.
Serious concern of indirectness was noted. The body of evidence does not provide certainty that rare serious adverse events were captured due to the short duration of follow-up (median: 3.3 months).
The effects noted are from an analysis of the initial enrollment group. A safety expansion group of children aged 5–11 years (1591 children in the vaccine arm and 788 children in the placebo arm) were not included because of the short duration of follow-up (median: 2.4 weeks). At the time of the data cutoff (October 8, 2021) 3 SAEs (infection of the knee, foreign body ingestion of a penny, epiphyseal fracture) were reported in 3 children (1 each) in the vaccine group. The pooled relative risks for the initial enrollment group and safety expansion group was 1.98 (95% CI: 0.22─17.70). All SAEs were assessed by the investigator as not related to the study intervention.
Very serious concern for imprecision was noted based on the 95% confidence interval crossing the line of no effect (1). The width of the confidence interval contains estimates for which different policy decisions might be considered. This outcome may be imprecise due to the small number of events during the observation period.
1 SAE (limb fracture) was reported in a participant in the BNT162b2 group, which was determined by the investigator to be unrelated to the study intervention.
2 SAEs (pancreatitis and abdominal pain) occurred in 1 placebo recipient.
Serious concern for imprecision given the wide 95% confidence interval, which cannot exclude the possibility of no difference between BNT162b2 and placebo.Appendix 1. Studies Included in the Review of Evidence
Appendix 1. Studies Included in the Review of Evidence
Last name first author, Publication year
Study design
Country (or more detail, if needed)
**Population**
Total population
N **intervention**
N comparison
Outcomes
Funding sourcePfizer, 2021 [*2*]
Phase II/III RCT
USA, Finland, Poland, Spain
Children aged 5─11 years
4,647
3,109
1,538
Symptomatic laboratory-confirmed COVID-19
Serious adverse events
Reactogenicity
Industry fundingAppendix 2. Databases and strategies used for systematic review
Appendix 2. Databases and strategies used for systematic review
Database
StrategyClinicaltrials.gov
**Inclusion:**Phase 1, 2, or 3 clinical trials that provided data on:
Children 5-11 vaccinated with Pfizer BioNTech
involved human subjects
reported primary data
included data relevant to the efficacy and safety outcomes specified in the PICO questions**Additional resources:** Unpublished and other relevant data by consulting with vaccine manufacturers and subject matter experts**International Vaccine Access Center (IVAC)**
IVAC inclusion criteria:
published or preprint study with adequate scientific details
includes group with and without infection or disease outcome
laboratory-confirmed outcome†
vaccination status confirmed in ≥90%§
studies assess one vaccine or pooled mRNA vaccines
includes participants who did or did not receive a COVID-19 vaccine¶
vaccine effectiveness estimate calculated comparing vaccinated to unvaccinated**Additional GRADE inclusion criteria:
restricted to PICO-defined population, intervention, comparison, and outcomes (or related outcomes if no direct data available)
outcomes assessed after booster dose of Pfizer-BioNTech vaccineArticles were eligible for inclusion if published or available on a pre-print server before 10/21/2021.
*Criteria included in the ongoing systematic review conducted by the International Vaccine Access Center (IVAC) and the World Health Organization (see https://view-hub.org/resources).
†Estimates of effectiveness against progression from infection disease are excluded.
§Studies were included with a lower proportion with confirmed vaccination status if there was sufficient cross-validation of vaccination status against confirmed information.
¶ Comparison group is not modelled or historical.Top of Page
							
					
							Last Reviewed:  November 5, 2021						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue